Travere Therapeutics Inc (TVTX) Directors and Executive Officers

Officers & Directors

Eric Dube
Chief Executive Officer and Director (Principal Executive Officer)

Suzanne Bruhn
Director

Timothy Coughlin
Director

Gary Lyons
Director

John A. Orwin
Director

Ron Squarer
Director

Sandra Calvin
Senior Vice President and Chief Accounting Officer (Principal Accounting Officer)

Ruth Williams-Brinkley
Director

Christopher Cline
Chief Financial Officer (Principal Financial Officer)

Roy D. Baynes
Director

Jeffrey A. Meckler
Director

Sandra E. Poole
Director ,

Travere Therapeutics Inc currently has 497 employees.

News about Travere Therapeutics Inc Key Personnel

Travere Therapeutics Pursues FDA Nod for FILSPARI in FSGS Treatment While Strategically Enhancing Workforce with Inducement Equity Awards,

Travere Therapeutics: Pioneering Advances in FSGS Treatment While Strategically Enhancing Workforce TalentIntroductionIn a landmark development, Travere Therapeutics, Inc. has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FILSPARI (sparsentan) as a treatment for focal segmental glomerulosclerosis (FSGS), a rare and severe kidney disease. This submission is supported by robust data from the Phase 3 DUPLEX and Phase 2 DUET clinical trials. Alongside this notable achievement, the company is also focusing on optimizing its workforce and enhancing productivity through strategic talent acquisition initiatives. 1. Advancements in Medical R...

Travere Therapeutics Submits sNDA to FDA for FILSPARI in IgA Nephropathy, While Stock Rallies on Market Confidence

Travere Therapeutics Aims for Full FDA Approval of FILSPARI in IgA Nephropathy as Stock Soars
Travere Therapeutics, a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, has recently submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking full approval for their drug FILSPARI (sparsentan) in the treatment of IgA Nephropathy (IgAN). This move comes after the company s successful acquisition of accelerated approval for FILSPARI in this indication, and marks a significant step towards providing a long-term treatment solution for patients suffering from this debilitating kidney disease.
IgA Nephropathy, often referr...